Among the above, PD-L1 is FDA-approved as a companion diagnostic for NSCLC, bladder cancer, triple-negative breast cancer, cervical cancer, and gastric/GEJ cancer [27]. This evidence concerns the gene CD274 and urinary bladder cancer.